Trials / NCT06492850
Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa
Status unknown Phase 1 / Phase 2 Gene therapy
- Sponsor
- Frontera Therapeutics
- Treatment
- FT-002
- Gene
- RPGR
- Conditions
- X-Linked Retinitis Pigmentosa (XLRP)
- Ages
- 8 Years to 45 Years
- Enrollment
- 32 participants
- Started
- 2024-04-01
- Main results expected
- 2025-08-01
- Results posted
- Not yet
- Record last updated
- 2024-07-09
What the study is testing
The aim of this study was to evaluate the safety, tolerability, and efficacy of one-time subretinal injection of FT-002 in male subjects (8-45 years of age) with RPGR (Retinitis Pigmentosa GTPase Regulator) gene mutation-associated X-linked retinitis pigmentosa, of XLRP. This study includes Phase I (dose escalation phase) and Phase II (dose expansion phase).
Where it runs
China (1)
- Peking Union Medical College Hospital, Beijing, Beijing Municipality (recruiting now)